Jul 27, 2021 / 06:00PM GMT
Deniel Mero -
Welcome to PropThink's Digital Conference. My name is Deniel Mero, Editor of PropThink. I will be hosting today's event. PropThink is a biotech-focused investment newsletter. PropThink Digital Conferences is a platform designed to give you access to subject matter experts, including prominent investors, executives, KOLs and others, with unique insight into health care investing.
We were intrigued by Medicenna after researching the IL-2 space as one of the hottest fields in oncology and has gotten the attention of big pharma and smart money. In 2018, Bristol Myers paid Nektar $1.8 billion upfront to codevelop their IL-2, an agonist in solid cancers. This deal set off a frenzy in IL-2.
By late 2019, Sanofi acquired preclinical IL-2 company, Synthorx, for $2.5 billion, beating out 3 other big pharma bidders in the process.
And in just the last month, private preclinical stage Synthekine raised over $100 million led by sophisticated bio funds.
So you have billions of dollars being thrown around to gain access to preclinical and early Phase I candidates, yet the IL-2
Medicenna Therapeutics Corp MDNA11 Program Update Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers